Chikungunya Fever
17
1
1
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.9%
1 terminated out of 17 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (17)
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
Trial of an Inactivated Chikungunya Virus Vaccine
A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
Real-World Study on Chinese Medicine for Treating Chikungunya Fever
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya
RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
Applying Wolbachia to Eliminate Dengue
Neurologic Manifestations of the Arbovirus Infection in Colombia
Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)
Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever
The Pilot Study of Chikungunya Virus Infections in Southern Taiwan
Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever
Impact of the Chikungunya Outbreak in Reunion Island on the Quality of Life After 10 Years
tDCS and Its Therapeutic Effects in CK Fever
Chikungunya Virus Vaccine Trial in Healthy Adults